<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940522</url>
  </required_header>
  <id_info>
    <org_study_id>AMAG-HPC-PK-010</org_study_id>
    <nct_id>NCT02940522</nct_id>
  </id_info>
  <brief_title>Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women</brief_title>
  <official_title>A Multi-Center, Randomized, Open-Label Study Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that a single dose of Makena® delivered SQ via auto-injector has comparable
      bioavailability to a single IM injection of Makena®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the maximum plasma concentration (Cmax)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Comparison of the maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of areas under the curve (AUC) to the last time with a concentration ≥ LLOQ [AUC0-t] and to infinity [AUCinf]</measure>
    <time_frame>8 weeks</time_frame>
    <description>Comparison of areas under the curve (AUC) to the last time with a concentration ≥ LLOQ [AUC0-t] and to infinity [AUCinf]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Tmax</measure>
    <time_frame>8 weeks</time_frame>
    <description>Comparison of PK parameter Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of AUC</measure>
    <time_frame>8 weeks</time_frame>
    <description>Comparison of PK parameter AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of t1/2</measure>
    <time_frame>8 weeks</time_frame>
    <description>Comparison of PK parameter t1/2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SQ) injection using an autoinjector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular injection (IM) using syringe and needle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Makena SQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Makena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Naturally or surgically postmenopausal women, with or without an intact uterus, aged 50
        to 75 years of age, inclusive. FSH levels greater than 40 mIU/mL

        Exclusion Criteria:

          1. Currently taking any estrogen/progesterone hormone replacement therapy (HRT).

          2. History of allergy or sensitivity to hydroxyprogesterone caproate, castor oil or any
             of the constituents of the study medications, or history of any drug hypersensitivity
             or intolerance

          3. Poorly controlled diabetes.

          4. History or current evidence of deep vein thrombosis, pulmonary embolism or arterial
             thromboembolic disease (e.g., stroke, myocardial infarction).

          5. Known, suspected, or current history of carcinoma of the breast.

          6. Subjects with a past history of breast cancer on aromatase inhibitors or selective
             estrogen receptor modulators.

          7. Known, suspected, or current history of hormone dependent tumor within the last 5
             years.

          8. Any current or recent (within previous 12 months) genital bleeding of unknown
             etiology.

          9. Receipt of any investigational drug within 30 days.

         10. Receipt of any prescription or OTC medications that are known to alter CYP3A4 or
             CYP3A5 levels (e.g., carbamazepine, St. John's Wort, ketoconazole, rifampin,
             ritonavir, alprazolam, azithromycin, loratadine, etc.) within 14.

         11. Any estrogen, progestin, or selective estrogen receptor modulator (SERM) treatment
             within specified time windows before the study start, ranging from 2 to 6 months.

         12. High blood pressure at the screening evaluation, defined as systolic blood pressure &gt;
             150 mm Hg or diastolic blood pressure &gt; 90 mm Hg.

         13. History of excessive alcohol consumption (on average more than 14 units of
             alcohol/week) during the past 12 months.

         14. Use of tobacco products within 30 days of the start of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Krop, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AMAG Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 24, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

